Acquired Hemophilia A after Tislelizumab Treatment in a Patient with Right Lung Squamous Cell Carcinoma

Keywords

acquired hemophilia A (AHA) - PD-1 - tislelizumab - right lung squamous cell carcinoma

• References

• 1 Knoebl P, Marco P, Baudo F. et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (04) 622-631
• 2 Schep SJ, van Dijk WEM, Beckers EAM. et al; Dutch Society of Haemophilia Treaters, The Netherlands. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol 2021; 96 (01) 51-59
• 3 Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: a systematic and critical literature review. Haemophilia 2018; 24 (01) 43-56
• 4 Sun B, Xue F, Feng Y. et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. Br J Haematol 2019; 187 (05) 653-665
• 5 Wang Y, Zhou S, Yang F. et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019; 5 (07) 1008-1019
• 6 Gokozan HN, Friedman JD, Schmaier AH, Downes KA, Farah LA, Reeves HM. Acquired hemophilia A after nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed with rituximab. Clin Lung Cancer 2019; 20 (05) e560-e563
• 7 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36 (17) 1714-1768
• 8 Delanoy N, Michot JM, Comont T. et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019; 6 (01) e48-e57
• 9 Hei Y, Yang R, Kong S, Zhang H, Chen Y. Pathological complete response following neoadjuvant tislelizumab monotherapy in treatment-naive locally advanced, MMR-deficient/MSI-high ascending colon cancer: a case report. J Clin Med 2022; 12 (01) 240
• 10 Zhang L, Geng Z, Hao B, Geng Q. Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Cancer Control 2022; 29: 10 732748221111296
• 11 Kruse-Jarres R, Kempton CL, Baudo F. et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 2017; 92 (07) 695-705
• 12 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (05) 433-446
• 13 Zheng X, Wei H. Organ-specific immune-related adverse events for PD-1 antibodies in lung cancer treatment. Front Oncol 2021; 11: 628243
• 14 Zubiri L, Allen IM, Taylor MS. et al. Immune-related adverse events in the setting of PD-1/L1 inhibitor combination therapy. Oncologist 2020; 25 (03) e398-e404
• 15 Gidaro A, Palmieri G, Donadoni M. et al. A diagnostic of acquired hemophilia following PD1/PDL1 inhibitors in advanced melanoma: the experience of two patients and a literature review. Diagnostics (Basel) 2022; 12 (10) 2559
• 16 Shetty SD, Ghosh K. Challenges and open issues in the management of acquired hemophilia A (AHA). Blood Cells Mol Dis 2015; 54 (03) 275-280
• 17 Tiede A, Collins P, Knoebl P. et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105 (07) 1791-1801
• 18 Collins P, Baudo F, Knoebl P. et al; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120 (01) 47-55